 Gemlyn George
Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombocytopenia | 4 | 2022 | 205 | 1.070 |
Why?
| | Anemia, Sickle Cell | 6 | 2026 | 312 | 0.960 |
Why?
| | Graft vs Host Disease | 4 | 2020 | 264 | 0.950 |
Why?
| | Hematopoietic Stem Cell Transplantation | 5 | 2020 | 676 | 0.840 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2021 | 23 | 0.680 |
Why?
| | Asparaginase | 1 | 2020 | 30 | 0.630 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 3 | 2026 | 17 | 0.610 |
Why?
| | Antithrombins | 1 | 2020 | 70 | 0.610 |
Why?
| | Venous Thrombosis | 1 | 2020 | 195 | 0.540 |
Why?
| | Carcinoma, Renal Cell | 1 | 2020 | 234 | 0.510 |
Why?
| | Platelet Factor 4 | 4 | 2026 | 36 | 0.510 |
Why?
| | Proteinuria | 1 | 2017 | 102 | 0.510 |
Why?
| | Thrombelastography | 1 | 2018 | 178 | 0.510 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 293 | 0.500 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2021 | 1141 | 0.490 |
Why?
| | Liver Cirrhosis | 1 | 2018 | 288 | 0.470 |
Why?
| | Kidney Neoplasms | 1 | 2020 | 412 | 0.450 |
Why?
| | Polyethylene Glycols | 1 | 2020 | 655 | 0.440 |
Why?
| | Hemopexin | 2 | 2025 | 38 | 0.430 |
Why?
| | beta-Thalassemia | 2 | 2025 | 40 | 0.410 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2017 | 497 | 0.390 |
Why?
| | Vaccination | 1 | 2021 | 1423 | 0.370 |
Why?
| | Multiple Myeloma | 3 | 2023 | 304 | 0.370 |
Why?
| | Hematologic Neoplasms | 2 | 2023 | 162 | 0.310 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1958 | 0.310 |
Why?
| | Hypertension, Pulmonary | 3 | 2026 | 1980 | 0.300 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2020 | 76 | 0.300 |
Why?
| | Stroke | 1 | 2017 | 1258 | 0.280 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 324 | 0.250 |
Why?
| | Iron | 2 | 2025 | 359 | 0.230 |
Why?
| | Biotinylation | 1 | 2025 | 37 | 0.230 |
Why?
| | Biotin | 1 | 2025 | 32 | 0.220 |
Why?
| | Haptoglobins | 1 | 2025 | 66 | 0.220 |
Why?
| | Cation Transport Proteins | 1 | 2026 | 118 | 0.220 |
Why?
| | Heme | 1 | 2025 | 89 | 0.210 |
Why?
| | Humans | 29 | 2026 | 144957 | 0.190 |
Why?
| | Erythrocyte Transfusion | 1 | 2025 | 231 | 0.190 |
Why?
| | Spleen | 1 | 2025 | 508 | 0.190 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 100 | 0.180 |
Why?
| | Middle Aged | 10 | 2026 | 35928 | 0.170 |
Why?
| | Upper Extremity Deep Vein Thrombosis | 1 | 2021 | 3 | 0.170 |
Why?
| | Retrospective Studies | 9 | 2021 | 17101 | 0.170 |
Why?
| | Central Venous Catheters | 1 | 2021 | 53 | 0.160 |
Why?
| | Adult | 11 | 2026 | 40506 | 0.160 |
Why?
| | Antibodies | 1 | 2022 | 403 | 0.160 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2020 | 89 | 0.160 |
Why?
| | Primary Myelofibrosis | 1 | 2020 | 8 | 0.160 |
Why?
| | Vaccines | 2 | 2022 | 389 | 0.160 |
Why?
| | Extracellular Vesicles | 1 | 2023 | 171 | 0.160 |
Why?
| | Lymphoma, Follicular | 1 | 2020 | 56 | 0.160 |
Why?
| | Proteome | 1 | 2025 | 518 | 0.160 |
Why?
| | Retreatment | 1 | 2020 | 77 | 0.160 |
Why?
| | Cryoglobulinemia | 1 | 2019 | 5 | 0.150 |
Why?
| | Ipilimumab | 1 | 2020 | 40 | 0.150 |
Why?
| | Transplantation, Homologous | 1 | 2020 | 415 | 0.150 |
Why?
| | Male | 14 | 2026 | 72406 | 0.150 |
Why?
| | Erythrocytes | 1 | 2025 | 757 | 0.150 |
Why?
| | Vasculitis | 1 | 2019 | 69 | 0.150 |
Why?
| | Withholding Treatment | 1 | 2019 | 81 | 0.140 |
Why?
| | Pyrimidines | 2 | 2020 | 533 | 0.140 |
Why?
| | Salvage Therapy | 1 | 2020 | 162 | 0.140 |
Why?
| | Pulmonary Embolism | 1 | 2021 | 244 | 0.140 |
Why?
| | Pyrazoles | 2 | 2020 | 510 | 0.140 |
Why?
| | Hypoxia | 1 | 2026 | 1199 | 0.140 |
Why?
| | Autoantibodies | 1 | 2026 | 1504 | 0.140 |
Why?
| | Recurrence | 2 | 2021 | 1135 | 0.140 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2019 | 127 | 0.140 |
Why?
| | Hodgkin Disease | 1 | 2020 | 171 | 0.130 |
Why?
| | Blood Platelets | 2 | 2022 | 400 | 0.130 |
Why?
| | Aged | 8 | 2026 | 25947 | 0.130 |
Why?
| | Thrombosis | 1 | 2021 | 393 | 0.130 |
Why?
| | Gastroesophageal Reflux | 1 | 2019 | 236 | 0.120 |
Why?
| | Liver | 1 | 2025 | 1888 | 0.120 |
Why?
| | Hospitals | 1 | 2020 | 732 | 0.110 |
Why?
| | Lung | 2 | 2025 | 4109 | 0.110 |
Why?
| | Disease Models, Animal | 4 | 2026 | 4569 | 0.110 |
Why?
| | Length of Stay | 1 | 2020 | 1337 | 0.110 |
Why?
| | Lymphocytes | 1 | 2016 | 382 | 0.100 |
Why?
| | Patient-Centered Care | 1 | 2019 | 544 | 0.100 |
Why?
| | Brain Ischemia | 1 | 2017 | 358 | 0.100 |
Why?
| | Female | 10 | 2026 | 78376 | 0.100 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 970 | 0.090 |
Why?
| | Anticoagulants | 3 | 2022 | 724 | 0.090 |
Why?
| | Celiac Disease | 1 | 2016 | 308 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 2118 | 0.090 |
Why?
| | Liver Transplantation | 1 | 2018 | 823 | 0.080 |
Why?
| | Heparin | 2 | 2022 | 244 | 0.080 |
Why?
| | India | 3 | 2019 | 218 | 0.080 |
Why?
| | Mice | 5 | 2026 | 18365 | 0.080 |
Why?
| | Transplantation, Autologous | 2 | 2023 | 292 | 0.080 |
Why?
| | Neutrophils | 1 | 2016 | 1134 | 0.080 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3415 | 0.080 |
Why?
| | Porphyromonas | 1 | 2009 | 3 | 0.080 |
Why?
| | Eubacterium | 1 | 2009 | 3 | 0.080 |
Why?
| | Bifidobacterium | 1 | 2009 | 21 | 0.080 |
Why?
| | Bacteroides | 1 | 2009 | 20 | 0.080 |
Why?
| | Adolescent | 5 | 2020 | 22453 | 0.070 |
Why?
| | Animals | 6 | 2026 | 38109 | 0.060 |
Why?
| | Proteomics | 2 | 2025 | 1195 | 0.060 |
Why?
| | Cohort Studies | 1 | 2017 | 5965 | 0.060 |
Why?
| | Intestines | 1 | 2009 | 358 | 0.060 |
Why?
| | Socioeconomic Factors | 1 | 2009 | 1327 | 0.050 |
Why?
| | Treatment Outcome | 1 | 2020 | 11695 | 0.050 |
Why?
| | Heme Oxygenase-1 | 1 | 2025 | 74 | 0.050 |
Why?
| | Aerosols | 1 | 2025 | 186 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2025 | 5997 | 0.050 |
Why?
| | Melphalan | 1 | 2023 | 43 | 0.050 |
Why?
| | Hemolysis | 1 | 2025 | 243 | 0.050 |
Why?
| | Ventricular Function, Right | 1 | 2025 | 297 | 0.050 |
Why?
| | Glycolysis | 1 | 2025 | 340 | 0.050 |
Why?
| | Cell Survival | 1 | 2025 | 1098 | 0.040 |
Why?
| | Thrombin | 1 | 2023 | 166 | 0.040 |
Why?
| | Cryopreservation | 1 | 2022 | 110 | 0.040 |
Why?
| | Obesity | 2 | 2019 | 3082 | 0.040 |
Why?
| | Blood Preservation | 1 | 2025 | 354 | 0.040 |
Why?
| | Catheters | 1 | 2021 | 75 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 573 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2022 | 851 | 0.040 |
Why?
| | Monocytes | 1 | 2023 | 538 | 0.040 |
Why?
| | Prevalence | 2 | 2019 | 2836 | 0.040 |
Why?
| | Vidarabine | 1 | 2020 | 32 | 0.040 |
Why?
| | Busulfan | 1 | 2020 | 16 | 0.040 |
Why?
| | Upper Extremity | 1 | 2021 | 112 | 0.040 |
Why?
| | Proteasome Inhibitors | 1 | 2020 | 40 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2022 | 255 | 0.040 |
Why?
| | Plasmapheresis | 1 | 2019 | 23 | 0.040 |
Why?
| | Diet | 2 | 2019 | 1275 | 0.040 |
Why?
| | Prednisolone | 1 | 2019 | 66 | 0.040 |
Why?
| | Prognosis | 2 | 2019 | 4293 | 0.040 |
Why?
| | Nitriles | 1 | 2020 | 205 | 0.040 |
Why?
| | Transplantation Conditioning | 1 | 2020 | 186 | 0.040 |
Why?
| | Rituximab | 1 | 2019 | 210 | 0.030 |
Why?
| | Milk | 1 | 2019 | 119 | 0.030 |
Why?
| | Remission Induction | 1 | 2019 | 308 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2025 | 1339 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2022 | 893 | 0.030 |
Why?
| | Piperidines | 1 | 2019 | 217 | 0.030 |
Why?
| | Lipids | 1 | 2023 | 710 | 0.030 |
Why?
| | Adenine | 1 | 2019 | 339 | 0.030 |
Why?
| | Young Adult | 3 | 2019 | 14126 | 0.030 |
Why?
| | Proteins | 1 | 2023 | 1022 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1385 | 0.030 |
Why?
| | Antinematodal Agents | 1 | 2016 | 7 | 0.030 |
Why?
| | Body Mass Index | 2 | 2019 | 2438 | 0.030 |
Why?
| | Edible Grain | 1 | 2016 | 49 | 0.030 |
Why?
| | Urban Population | 1 | 2019 | 491 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2852 | 0.030 |
Why?
| | Macrophages | 1 | 2023 | 1511 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2016 | 427 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2019 | 8279 | 0.030 |
Why?
| | Time Factors | 1 | 2026 | 7183 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1524 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 615 | 0.030 |
Why?
| | Logistic Models | 1 | 2019 | 2119 | 0.020 |
Why?
| | Sex Factors | 1 | 2019 | 2114 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2016 | 760 | 0.020 |
Why?
| | Age Factors | 1 | 2019 | 3335 | 0.020 |
Why?
| | Inflammation | 1 | 2023 | 2880 | 0.020 |
Why?
| | DNA, Ribosomal | 1 | 2009 | 94 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5417 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 7997 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2009 | 245 | 0.020 |
Why?
| | Dietary Carbohydrates | 1 | 2009 | 151 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2009 | 342 | 0.020 |
Why?
| | Child | 2 | 2023 | 22657 | 0.020 |
Why?
| | Energy Intake | 1 | 2009 | 500 | 0.020 |
Why?
| | Risk Factors | 1 | 2021 | 10792 | 0.020 |
Why?
| | United States | 1 | 2023 | 15988 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 2197 | 0.010 |
Why?
|
|
George's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|